|Other Names||Protein SSX4, Cancer/testis antigen 54, CT54, SSX4, SSX4A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13213c was selected from the Center region of SSX4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Could act as a modulator of transcription.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The product of this gene belongs to the family of highlyhomologous synovial sarcoma X (SSX) breakpoint proteins. Theseproteins may function as transcriptional repressors. They are alsocapable of eliciting spontaneously humoral and cellular immuneresponses in cancer patients, and are potentially useful targets incancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes havebeen involved in the t(X;18) translocation characteristically foundin all synovial sarcomas. This translocation results in the fusionof the synovial sarcoma translocation gene on chromosome 18 to oneof the SSX genes on chromosome X. Chromosome Xp11 contains asegmental duplication resulting in two identical copies of synovialsarcoma, X breakpoint 4, SSX4 and SSX4B, in tail-to-tailorientation. This gene, SSX4B, represents the more centromericcopy. Two transcript variants encoding distinct isoforms have beenidentified for this gene.
Ayyoub, M., et al. J. Immunol. 174(8):5092-5099(2005)Ross, M.T., et al. Nature 434(7031):325-337(2005)Gure, A.O., et al. Int. J. Cancer 101(5):448-453(2002)Brodin, B., et al. Gene 268 (1-2), 173-182 (2001) :Chen, C.H., et al. Cancer Lett. 164(2):189-195(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.